← Back to all trials
Recruiting
NCT07416604
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Conditions: Hemophilia A
Sex: All
Ages: 12 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 360
Sponsor: Hoffmann-La Roche
Location: Center for Inherited Blood Disorders Orange California
Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of severe (FVIII:C \5 IU/dL and \
Source: ClinicalTrials.gov (NCT07416604). StuddyBuddy aggregates publicly available trial information.
